Agfa-Gevaert: Share buyback program – regulated information

Mortsel, Belgium – June 7, 2021 – 5:40 p.m. CET

Within the framework of the share buyback program which was announced in the press release of March 10, 2021, Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels.

The authorization to acquire own shares was granted to the Board of Directors by the Extraordinary General Meeting of Shareholders of May 12, 2020.

Agfa-Gevaert NV has requested a financial intermediary to repurchase
Agfa-Gevaert shares for a maximum amount of 50,000,000 Euro on its behalf under the terms of an initial discretionary mandate agreement with validity until March 31, 2022, effective as from April 1, 2021.

On June 4, 2021, the Agfa-Gevaert Group held 1,516,832 own shares, which represents 0.90% of the total number of shares of the Group.

Detailed operations per day:

Date	Number of shares	Average price (€)	Minimum price (€)	Maximum price (€)	Total price (€)
May 31, 2021	22,966	3.9042	3.8900	3.9200	89,663.86
June 1, 2021	54,534	3.9395	3.9050	3.9700	214,836.69
June 2, 2021	43,896	3.9355	3.9200	3.9450	172,752.71
June 3, 2021	26,587	3.9348	3.9150	3.9500	104,614.53
June 4, 2021	21,567	3.9536	3.9350	3.9650	85,267.29
Total	169,550	3.9347			667,135.08

About Agfa

The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing industry. In 2020, the Group realized a turnover of 1,709 million Euro.

Contact:
Viviane Dictus
Director Corporate Communication
T +32 (0) 3 444 71 24
E viviane.dictus@agfa.com

Johan Jacobs
Corporate Press Relations Manager
T +32 (0)3/444 80 15
E johan.jacobs@agfa.com

Attachments

• Press release in pdf
• Persbericht in pdf

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.